Mirador Therapeutics

Our Chairman and CEO, Mark McKenna, was recently featured on the BioWorld Insider Podcast. In the episode, he delved into key insights about our mission at Mirador, discussing our innovative work in #precisionmedicine for inflammation and immunology (I&I) and touched upon macro industry trends shaping the future of healthcare. Listen to the full episode here: https://lnkd.in/e-_fR8bj

The Mirador team believes that now is the right time to bring precision medicine into immunology for the first time by leveraging our Mirador360™ development engine. We are motivated to make a revolutionary leap forward in #drugdiscovery, targeting multiple disease areas starting with immunology and inflammation (I&I) diseases, with the aim of delivering better outcomes for patients. Read more about our vision in Jeff Clemetson's San Diego Business Journal piece below! 

We are led by a highly talented executive team with proven experience creating best places to work. We are driven to help patients in need, foster personal and professional growth, unlock our potential as a team, and to deliver exceptional results. If you have a passion for being a market leader, discovering and developing disruptive therapies, improving the lives of patients, love what you do and want to help us build a next-generation and best places to work company—we want to hear from you. Check out our latest opportunities through the link here: https://lnkd.in/eRwcMwNC #biotechjobs

Thanks to Nasdaq for helping us celebrate our launch by putting the news on the big screen! We couldn't be more proud of all our Mirador team members for their hard work in making yesterday possible as we seek to improve the lives of people with immune-mediated diseases through innovative #precisionmedicine. Learn more: https://miradortx.com

We're thrilled to introduce Mirador Therapeutics! Our team is on a mission to revolutionize #precisionmedicine for immune-mediated inflammatory and fibrotic diseases by leveraging our proprietary Mirador360™ development engine. Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed, Fairmount and others. Read more about the potential we have to provide important new treatment options for patients with cutting-edge #datascience in the release below.